Anyone with a prescription can get semaglutide
Even for employers betting that the potential long-term health benefits associated with GLP-1 utilizations and weight loss - including reduced risks for cardiovascular and kidney disease - will ultimately outweigh the substantial upfront costs, those rising upfront costs are becoming problematic
Magnitude of weight loss Clinical trials have reported that retatrutide can facilitate more substantial weight loss compared to Ozempic, with participants achieving average reductions of up to 24% of their baseline body weight
odds ratio 3.3536.97), rates of pulmonary aspiration (0.1% to 0.2%) remain quite low, with no significant increase in comparison to control groups
Theyre meant to fill in the gaps when commercial products are not appropriate or available, Shabbir Imber Safdar, executive director of the San Francisco-based Partnership for Safe Medicines, told IBJ
More ambitiously, we can imagine AI screening draft prescriptions and auto-initiating PAs with pre-populated justifications